ARTICLE | Company News

Arris deal

February 7, 1994 8:00 AM UTC

Kabi Pharmacia AB (Sweden) will use ARRS's artificial intelligence technology for an undisclosed Kabi drug discovery program. The technology analyzes data developed from both compound library screening and structure-based drug analysis to generate a predictive model of activity of targeted compounds and receptors. ARRS (South San Francisco) believes that the approach will enable it to use a virtual assay process to design and optimize compounds before they need to be synthesized and tested in the lab. ...